A Dal­las biotech halts TIL ther­a­py tri­als — shares crater near­ly 30%

A Texas biotech at­tempt­ing to cre­ate new cell ther­a­pies has hit pause on en­roll­ment in clin­i­cal tri­als be­cause of man­u­fac­tur­ing is­sues, and the com­pa­ny’s shares sank about 30% af­ter the open­ing bell.

In­stil Bio said it has in­formed the FDA and reg­u­la­tors in Cana­da and the UK of its de­ci­sion to stop let­ting new pa­tients in­to the study as it looks in­to man­u­fac­tur­ing is­sues for ITIL-168, the com­pa­ny’s lead tu­mor in­fil­trat­ing lym­pho­cyte (TIL) ther­a­py, which is in mid- and ear­ly-stage stud­ies for ad­vanced melanoma and var­i­ous sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER